# FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

> **NCT06193525** · PHASE2 · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 66 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT06193525
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-09-16
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06193525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06193525, "FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06193525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*